MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02518nam a22002537a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
MED20160010 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20240720152931.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
171013b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
FEU-NRMF MEDICAL LIBRARY |
| 041 ## - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
ENGLISH |
| 050 ## - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
MED20160010 |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Andor, Julius M., MD. |
| Relator term |
author |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
The Effect of rebamipide as adjunct therapy with proton-pump inhibitor in patients with upper gastrointestinal bleeding : |
| Remainder of title |
a retrospective study / |
| Statement of responsibility, etc. |
Julius M. Ador and Roy Caballero. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc. |
Fairview, Quezon City |
| Name of publisher, distributor, etc. |
Department of Medicine, FEU-NRMF, |
| Date of publication, distribution, etc. |
2016 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
15 pages: |
| Other physical details |
illustrations; |
| Dimensions |
(in folder) |
| 336 ## - CONTENT TYPE |
|---|
| Source |
text |
| Content type term |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Source |
unmediated |
| Media type term |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Source |
volume |
| Carrier type term |
rdacarrier |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
ABSTRACT: Rebamipide, as a gastroprotective agent, is currently not included in the treatment recommendations of Upper Gastrointestinal Bleeding (UGIB). This retrospective cohort study determined the effect of Rebamipide as adjunct therapy with Proton-pump Inhibitor (PPI) in patients with UGIB admitted in FEU-NRMF Medical Foundation. A clear review was conducted within 5 years duration. Patients were divided into two groups: PPI alone vs. PPI + Rebamipide. 390 patients/cases were included in this study: 149 PPI alone cases and 241 PPI +Rebamipide cases. Resolution of signs of bleeding as to hematemesis, melena or hematochezia within 5 days duration was noted, as well as, the specific duration/time of resolution of signs of bleeding. Among 149 cases with PPI alone, 14.09% (21 cases) had resolution of signs within 5 days; while among those 241 cases with PPi + Rebamipide, the rate of resolution was 93% (224 cases). The rate difference was statistically significant wherein the resolution of signs of bleeding was significant association with PPI + Rebamipide intervention (p<0.001). In addition, the average time of resolution of the PPi alone group was 4.00 days +/-1.22, median days 4, and within an absolute range of 2-6 days resolution. On the other hand, the PPI + Remabipide group had average resolution time of 3.09 days +/ -0.95, with median days of 3, and within the absolute range of 2-5 days. In conclusion, Rebamipide + PPI is more effective than PPI alone in the treatment of UGIB. Also, Rebamipide may be an effective adjunct therapy with PPI in shortening the duration of UGIB. |
| 521 ## - TARGET AUDIENCE NOTE |
|---|
| Target audience note |
Research - Department of Medicine |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Relator code |
supevising consultant |
| Personal name |
Caballero, Roy, MD. |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
Research |
